In fact, as the typically relapsing course of MS carries the need to repeat pulsed methylprednisolone treatment several times, in patient with high disease activity an early treatment with a second‐line DMD such as natalizumab or fingolimod should be considered to more effectively reduce disease activity. The gene discussed is DMD; the disease is myeloid sarcoma.